Vitamin B1 for Period Pain: What the 87% Cure Claim Leaves Out

A claim that vitamin B1 cures most period pain sounds unusually decisive. Before buying a bottle, check whether its quoted percentage compares treatment with placebo, or describes what happened after everyone had received the vitamin.

Where the 87% figure comes from

A 1996 paper¹ studied 556 girls aged 12–21 with moderate to very severe primary dysmenorrhea. Its abstract describes 100 mg of thiamine hydrochloride daily for 90 days, and reports 87% with complete relief, 8% with partial relief and 5% with no effect.¹

Crucially, the 87% combined the “active treatment first” and “placebo first” groups after vitamin treatment. It is not a finding that 87% improved on B1 while a simultaneously untreated group did not. The abstract reports unchanged results two months later.¹

We verified the original abstract, but could not access the full paper. A combined treatment result and a short follow-up cannot establish a permanent cure or explain the cause of someone’s cramps.

What the review could use from that study

The 2016 Cochrane review describes a crossover design: one group received active treatment before placebo, while the other received placebo before active treatment. It considered the older study’s data unsuitable for its quantitative analysis. Allocation concealment was unclear, and final outcomes were unavailable for 24 participants.²

That helps explain why a large-looking headline can coexist with an uncertain evidence assessment. The group comparison, missing outcomes and reporting quality determine what conclusions a trial can support.

A later placebo trial reported lower pain scores

A study published in 2014 enrolled 240 high-school students aged 13–18 in Urmia, Iran, assigning 60 to each of four groups: B1, fish oil, their combination or placebo. The B1 dose was 100 mg daily for two months.³

In Table 2, mean pain scores were 4.11 with B1 versus 6.81 with placebo after one month, and 2.38 versus 7.28 after two months. Differences were significant.³

The report has numerical presentation problems: Table 1 prints placebo scores above the scale’s range, while Table 2 gives plausible values. We do not reconstruct the inconsistent duration figures.³

Participants were not allowed rescue pain medicine during the protocol. That makes the experiment different from adding B1 to a person’s usual cramp treatment. A clearly reported adverse-event comparison is missing.³

Cochrane found no clear additional pain benefit from combining fish oil with B1, compared with B1 alone, in this trial. A combination bottle therefore cannot claim an established advantage from these data.²

The vitamin E comparison had no placebo group

Another 2014 report described a single-blind trial⁴ in 90 students aged 18–26 in Mashhad, Iran. It compared B1, 100 mg daily from cycle day 15 until the next period, with vitamin E, 400 IU daily for five days around menstruation, for three cycles.⁴

Mean pain scores on a 100-mm scale decreased from 48.69 to 36.34 with B1 and 55.77 to 45.14 with vitamin E. The authors reported no significant difference between groups.⁴

Without placebo or a usual-care control, those decreases cannot isolate either vitamin’s effect. Failure to find a difference also does not establish that the treatments are equally effective. The paper’s recommendation to use them as alternatives to standard treatment goes beyond what this comparison can establish.⁴

A research dose is much larger than a dietary requirement

NIH’s Office of Dietary Supplements lists 1.1 mg daily as the recommended dietary allowance for women aged 19 and over, and 1.0 mg for girls aged 14–18. Those are nutritional requirements for healthy people. They are not cramp-treatment doses.⁵

The 100-mg study doses are approximately 91 times the adult female allowance, calculated from those figures. A trial using that dose does not prove that period pain identifies a deficiency, or that a higher dose would work better.

Thiamine is water-soluble, but that fact does not establish unlimited safety. No tolerable upper intake level was set because of insufficient reports of harms; ODS⁵ specifically notes that excessive intake could still have adverse effects.⁵

Cochrane rated the supplement evidence low or very low in quality, with limited safety reporting. Its assessment supports further research rather than a dependable cure claim.²

Keep the pain assessment on the calendar

The NHS⁶ recommends clinical review when pain stops usual daily activities, periods become more painful, heavier or irregular, or there is pain during sex, urination or bowel movements, or bleeding between periods. Severe pain, or pain worse than usual that painkillers have not helped, needs urgent assessment. In England, its advice is an urgent GP appointment or NHS 111; elsewhere use the appropriate local service.⁶

Its treatment options include heat and gentle movement, suitable painkillers, and clinician-guided anti-inflammatory medicines or contraception. Choosing among them depends on symptoms, medical history and whether another condition is causing the pain.⁶

Bring a supplement’s label and record when you took it alongside pain scores, missed activities and other treatments. Chapter 7, “Cramps That Stop You,” in Period, Handled explains the supplement evidence and uses the Pain Kit and Period Scorecard to prepare treatment and track its effect. Pain that keeps interrupting your month deserves a care plan even if a product advertises a cure.